Author: Zoulim, Fabien

Source: Expert Opinion on Emerging Drugs, Volume 12, Number 2, May 2007 , pp. 199-217(19)

Publisher: Informa Healthcare

Abstract:

Chronic hepatitis B remains a treatment challenge despite the availability of new nucleoside analogs. This is due to the persistence of viral infection during therapy, which exposes the patient to the risk of developing antiviral drug resistance. Therefore, new polymerase inhibitors are needed to manage resistance to existing drugs and new trials of combination therapy are required to delay drug resistance. In the future, antiviral agents targeting other steps of the viral life cycle will be needed to achieve antiviral synergy and prevent antiviral drug resistance. Immune modulators are also expected to enhance antiviral response and to achieve sustained response. Discovery of new antiviral drugs and design of new treatment strategies are, therefore, needed to manage this disease, which is still the main cause of cirrhosis and hepatocellular carcinoma worldwide.

Keywords: chronic hepatitis; hepatitis B; nucleoside analogs; polymerase inhibitors; viral resistance

Document Type: Research article

DOI: http://dx.doi.org/10.1517/14728214.12.2.199

Affiliations: 1: 1INSERM, U871, 151 cours Albert Thomas, 69424 Lyon cedex 03, France +33 472681970; +33 472681971;, Email: zoulim@lyon.inserm.fr

Publication date: 2007-05-01

More about this publication?

• Editorial Board
• Information for Authors
• Subscribe to this Title
• Terms & Conditions
• ingentaconnect is not responsible for the content or availability of external websites

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Zoulim, Fabien

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers